GVK Biosciences has unveiled a new brand CLINOGENT in the clinical development industry. CLINOGENT provides end-to-end clinical development services. From offering bioequivalence studies for generic pharma and late phase patient-based clinical studies for research-based companies, CLINOGENT brings expertise in delivering solutions to complex data analysis and medical communication problems to customer’s the world over. CLINOGENT will endeavour to provide innovative solutions to all the clinical and scientific challenges that their customers face in the business.
Manni Kantipudi, Chief Executive Officer, GVK BIO said, “CLINOGENT will be a unique clinical development service provider from India, as it will be able to address the clinical needs of both innovator bio-pharmaceutical and generics companies world-wide. I am confident this step will bring greater focus on delivering innovative and intelligent solutions and will make significant contributions in the clinical development value chain of our customers.”
EP News Bureau – Mumbai